aibioMira Pharmaceuticals gets Nasdaq bid price deficiency notice; deadline is January 25, 2027
Tickers MIRA
Nasdaq told Mira Pharmaceuticals on July 27, 2026 that its common stock no longer meets the $1 minimum bid price. The company has until January 25, 2027 to regain compliance, and it reported a 2025 net loss of $10.4 million on cash used in operations of $4.7 million.
Key facts
- Company
- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
- News type
- Listings
- Primary source
- MIRA PHARMACEUTICALS, INC. Form 8-K filed July 31, 2026 (SEC EDGAR)
Mira Pharmaceuticals, Inc. (Nasdaq: MIRA) received a deficiency letter from Nasdaq on July 27, 2026, because its common stock no longer meets the minimum bid price requirement of $1 per share. The company disclosed the letter in a Form 8-K filed July 31, 2026. The stock continues to trade on the Nasdaq Capital Market under the symbol "MIRA," and the letter has no immediate effect on the listing.
What the letter says
The letter came from the Listing Qualifications Staff of The Nasdaq Stock Market LLC. It is based on the closing bid price of the common stock for the 30 consecutive business days ended July 24, 2026. The Staff said the company does not meet the minimum bid price requirement in Nasdaq Listing Rule 5550(a)(2). The 8-K states that the letter "does not result in the immediate delisting" of the stock.
Under Nasdaq Listing Rule 5810(c)(3)(A), Mira has 180 calendar days, until January 25, 2027, to regain compliance. To do so, the closing bid price must be at least $1 per share for a minimum of ten consecutive business days within that period.
A second period, and a possible delisting
If Mira does not regain compliance in the first 180 days, it may be able to seek a second 180-day period. That requires the company to meet the market value of publicly held shares requirement and the other initial listing standards for the Nasdaq Capital Market, apart from the bid price test. It must also tell Nasdaq in writing that it intends to cure the deficiency in that period by effecting a reverse stock split, if necessary. A reverse stock split combines existing shares into a smaller number of shares.
If the Staff concludes that Mira cannot cure the deficiency, or that it is not eligible for a second period, Nasdaq will notify the company that its stock will be subject to delisting. The company could then appeal to a Nasdaq Hearings Panel. The 8-K says there is no assurance that such an appeal would succeed. Mira says it will monitor the bid price and consider options to resolve the deficiency, and it adds that there is no assurance it will regain compliance.
The company's finances
The annual report on Form 10-K, filed March 31, 2026, reports a net loss of $10.4 million for 2025, up from $7.9 million in 2024. Cash used in operations was $4.7 million in 2025, down from $5.6 million a year earlier. Research and development expense was $1.7 million, compared with $3.3 million in 2024. The auditor's report on the 2025 financial statements contains an explanatory paragraph on the company's ability to continue as a going concern, and the company says its losses and negative cash flows raise substantial doubt about that ability absent adequate new debt or equity financing. The company's risk factors also state that if it fails to maintain Nasdaq compliance, its shares may be delisted, which would make future debt or equity financing harder to obtain.
The pipeline is early
The company holds exclusive rights in the United States, Canada and Mexico to three candidates: Ketamir-2, MIRA-55 and SKNY-1. Ketamir-2, an oral NMDA receptor modulator being developed for chemotherapy-induced peripheral neuropathy, has completed a Phase 1 trial in healthy volunteers. The 10-K, filed in March, says Mira planned a Phase 2a trial in that condition in the first half of 2026, subject to regulatory feedback and site readiness; the 8-K does not say whether it has started. The Phase 1 trial was run in healthy volunteers, so it does not test effect in patients.
MIRA-55 is in preclinical development for inflammatory pain and conditions including anxiety and cognitive impairment. SKNY-1 is also preclinical. Mira acquired SKNY Pharmaceuticals, Inc. on September 29, 2025. The 10-K describes SKNY as a private company and a related party. The company is targeting an investigational new drug submission for SKNY-1 in 2026, subject to completing required studies, manufacturing readiness, regulatory interactions and available capital resources. The Drug Enforcement Administration has concluded that Ketamir-2, MIRA-55 and SKNY-1 are not controlled substances under the Controlled Substances Act.
Who is involved
Chief Executive Officer Erez Aminov signed the 8-K. The 10-K signature page lists Aminov as Chief Executive Officer and Chairman and Alan Weichselbaum as Chief Financial Officer.